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The vitamin K epoxide reductase complex 1 gene (VKORC1) is commonly assessed to predict warfarin sensitivity. In this study, a
new nested allele-specific multiplex polymerase chain reaction (PCR) method that can simultaneously identify single nucleotide
polymorphisms (SNPs) atVKORC1 381, 861, 5808, and 9041 for haplotype analysis was developed and validated. ExtractedDNAwas
amplified in the first PCR DNA, which was optimized by investigating the effects of varying the primer concentrations, annealing
temperature, magnesium chloride concentration, enzyme concentration, and the amount of DNA template. The amplification
products produced from the first round of PCR were used as templates for a second PCR amplification in which both mutant
and wild-type primers were added in separate PCR tubes, followed by optimization in a similar manner. The final PCR products
were resolved by agarose gel electrophoresis and further analysed by using a VKORC1 genealogic tree to infer patient haplotypes.
Fifty patients were identified to have H1H1, one had H1H2, one had H1H7, 31 had either H1H7 or H1H9, one had H1H9, eight had
H7H7, and one had H8H9 haplotypes. This is the first method that is able to infer VKORC1 haplotypes using only conventional
PCR methods.
1. Introduction
Warfarin is a blood-thinning drug that has been studied
extensively and confirmed to show interindividual variability
in efficacy due to genetic polymorphism. To date, sensitiv-
ity to warfarin has been significantly associated with the
cytochrome P450 (CYP2C9) and vitamin K epoxide reduc-
tase complex 1 (VKORC1) genes [1–3]. Many studies have
provided convincing evidence that the combined genotyping
ofCYP2C9 andVKORC1 helps to predict the appropriate war-
farin dosage for a patient and reduces the incidence of adverse
effects [4, 5]. Based on these data, the FDA has changed its
warfarin use guidelines to recommend genotyping to aid in
initial warfarin dosing [6].
Several researchers have already developed PCRmethods
for the simultaneous detection of multiple CYP2C9 single
nucleotide polymorphisms (SNPs), which can be very useful
in clinical practice. In contrast,VKORC1 SNPs have only been
studied relatively recently [7, 8] and multiplex PCR methods
for these SNPs are not yet available. At present, the most
comprehensive method for determining warfarin sensitivity
based on the VKORC1 gene is by identifying whether an
individual carries the H1, H2, H7, H8, or H9 haplotype; at
least four SNPs are required to delineate the haplotypes [9].
The H1 and H2 haplotypes are correlated with a low warfarin
dosage requirement, whileH7,H8, andH9 are correlatedwith
a higher dosage requirement.
Due to interethnic genetic variability, Lee et al. have
suggested that, for an Asian population, a single VKORC1
SNP is sufficient to delineate whether an individual will
require a low or high dosage of warfarin [10]. A retrospective
study using only VKORC1 381 as predictor of VKORC1
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haplotypes has been validated [11]. However, the dosing
model is still inadequate; although it successfully explains
60.2% of warfarin dosing variability, the model overestimates
the required daily warfarin dose by 50% on average in 11 out
of 108 subjects.
PCR methods for other VKORC1 SNPs, especially
VKORC1 3673 (also known asVKORC1−1639G>A), have also
been described extensively [12–14]. In addition, a capillary
electrophoresis method that can simultaneously detect SNPs
in CYP2C9, VKORC1, and gamma-glutamyl carboxylase
(GGCX) has been developed. However, all of these methods
were designed to detect only a single VKORC1 SNP [15],
and the detection of GGCX SNPs may not be necessary due
to its limited utility in determining warfarin dosage [16].
There exist real-time PCRmethods coupled with fluorescent-
labeled probes that can singly detect CYP2C9∗2, CYP2C9∗3,
and a VKORC1 [17, 18] which are tedious when carried out.
Single multiplex real-time PCR methods that can simultane-
ously detect CYP2C9∗3 and a VKORC1 SNP [19] also exist.
However, even though real-time PCR analysis is rapid and
more sensitive than conventional PCR method, it requires
a more stringent sample processing and not all laboratories
were equipped with real-time thermal cyclers which tend
to be more expensive than conventional thermal cycler.
Moreover, real-time PCR methods are only able to detect a
single VKORC1 variant at one time. Therefore, in an effort to
generate a simpler method without sacrificing the prediction
accuracy of VKORC1, we developed a new nested allele-
specific multiplex polymerase chain reaction (PCR) method
that is able to simultaneously genotype the VKORC1 381, 861,
5808, and 9041 SNPs.
2. Materials and Methods
2.1. Source of DNA. The method was approved by the
Research Ethics Committee (Human) of Universiti Sains
Malaysia. Malay patients (𝑛 = 93) between 32 and 85 years
old who received warfarin therapy were recruited from the
Specialised Medicine Clinic of the Hospital Universiti Sains
Malaysia between March 2008 and October 2010. Blood
(3mL) was drawn from each of the subjects after signing
written informed consents. DNA was extracted from 200 𝜇L
of the collected blood using a QIAamp DNA Blood Mini Kit
(Qiagen, Hilden).
2.2. Primer Design. To increase the specificity of the PCR
amplification, a two-step PCR was performed. The first step
PCR (PCR1) primer pair was designed to decrease the overall
length of the genomic templates, while the second step
PCR (PCR2) primer pair was designed to amplify DNA
sections within the PCR1 product containing the SNP sites.
To differentiate between wild-type and mutant genotype, the
3󸀠-ends of the wild-type and mutant PCR2 primers were
designed to have one nucleotide difference. The wild-type
primer amplifies only samples for wild-type alleles, and the
opposite is true for the mutant primer.
The specificity of each of the primers was checked using
a Basic Local Alignment Tool (BLAST) from NCBI. Highly
specific forward and reverse primer candidates were paired
with one another and were checked for their amplification
specificity and melting temperature (𝑇
𝑚
) in silico using
Primer-BLAST from NCBI. The possible formation of cross-
dimers was further checked using the NetPrimer Java appli-
cation (http://www.premierbiosoft.com/). Only primers that
were predicted to specifically amplify the SNP sites with sim-
ilar melting temperature (𝑇
𝑚
) and yield a reasonable product
size were selected for the development of the VKORC1
amplification method. The primers selected for PCR1 and
PCR2 are listed in Table 2.
2.3. Multiplex PCR Optimisation. Polymerase chain reaction
method optimisation was first carried out for PCR1 using
DNA templates from only a single subject. The method
optimisation consisted of a series of investigations that
tested for the optimum primer concentrations, annealing
temperature, magnesium chloride (MgCl
2
) concentration,
and enzyme concentration. The optimised PCR1 products
were then diluted 200 times before being used as the DNA
templates for PCR2 method optimisation. An individual
sample from PCR1 was divided into two portions in separate
tubes for PCR2 amplification, in which each tube amplifies
mutant and wild-type variants, respectively.
The stock reagents used for both PCRs were 10X Taq
buffer (Fermentas, Vilnius), 5.0U/𝜇L Taq polymerase (Fer-
mentas, Vilnius), 25mMMgCl
2
(Fermentas, Vilnius), 10mM
dNTP (Fermentas, Vilnius), 10 𝜇M forward and reverse
primers, respectively (1st Base Laboratory, Selangor), and
autoclaved distilled water. The total reaction volume of a
single PCR amplification was 20 𝜇L. All PCR reactions were
performed in aMyCyclerThermalCycler (Bio-Rad Laborato-
ries, Hercules).The optimised PCR1 and PCR2methods were
then tested for reproducibility in samples from 20 subjects.
2.4. Genotyping Method. The genotype data from PCR2 were
used to infer subject haplotypes using haplotyping table
revised from Rieder et al. [9] (Table 1). A subject may have
a homozygous (e.g., H1H1) or heterozygous haplotype (e.g.,
H1H7).
2.5. Sequencing. All PCR products were analysed by agarose
gel electrophoresis (1%).The expected band sizes are listed in
Tables 2 and 3. PCR amplification products for PCR2 were
sent to a commercial laboratory for sequencing. Sequencing
was performed using an Applied Biosystems 3730 XLGenetic
Analyzer (Applied Biosystems, Foster City). The SNPs were
analysed by aligning the result sequence with the reference
gene sequence AY587020 using the BioEdit Sequence Align-
ment Editor (version 7.0.5.3).
3. Results
The optimised reagent concentrations for both PCR1 and
PCR2 are similar except for the primer pair concentration
for PCR1 which is 0.60 𝜇M for VKORC1 381 and 861 and
0.25 𝜇M for both VKORC1 5808 and 9041. In PCR2, the
primer pair concentrations were 0.70, 0.05, 0.09, and 0.06𝜇M
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Table 1: The four SNPs required to infer the VKORC1 haplotypes. The replacement of VKORC1 381 with VKORC1 3673, 6484, 6853, or 7566
was possible because these five SNPs were tightly linked.
VKORC1 SNP HGSV Haplotype
WT variant Mut variant
381 296C>T C = see 5808 T = see 9041
5808 5723T>G T = H1 G = H2
9041 8956G>A G = H9 A = see 861
861 776C>A C = H7 A = H8
Table 2: Primers used in PCR1 and PCR2.
Sequence (5󸀠 to 3󸀠) Location Length (bp) Product size (bp) 𝑇
𝑚
(∘C)
Primers for PCR1
381 & 861
Com (F) GCCCAGGAGTTAGAGGCAACATAAC 257–281 25 1060 66.2
Com (R) CAGCTTTCTCTGATCTCCTGGTGTG 1316–1292 25 66.2
5808
Com (F) ATTCTGGAGTCTGGGATCGGTGTG 5546–5569 24 398 66.3
Com (R) ACCCCAGAATCTCCAGCTCCCTG 5943–5921 23 68.1
9041
Com (F) CAGCTCCTGGCATCTAGGTAGTGC 8604–8627 24 853 68.0
Com (R) CTTCCAGGTGTGTGCTCAGCCTTC 9456–9433 24 68.0
Primers for PCR2
381
381 & 861 Com (R) CAGCTTTCTCTGATCTCCTGGTGTG 1316–1292 25 66.2
WT (F) AGCACTTTAGGAAGCCAAGGAGGGC 357–381 25 960 67.9
Mut (F) AGCACTTTAGGAAGCCAAGGAGGGT 357–381 25 960 66.2
861
381 & 861 Com (R) CAGCTTTCTCTGATCTCCTGGTGTG 1316–1292 25 66.2
WT (F) AAACTCCTGACCTCAGGTGATCCAC 837–861 25 480 66.2
Mut (F) AAACTCCTGACCTCAGGTGATCCAA 837–861 25 480 64.6
5808
Com (F) ATTCTGGAGTCTGGGATCGGTGTG 5546–5569 24 66.3
WT (R) CGCCAACACCCCCCTTCA 5825–5808 18 280 71.7
Mut (R) CGCCAACACCCCCCTTCC 5825–5808 18 280 70.8
9041
Com (R) CTTCCAGGTGTGTGCTCAGCCTTC 9456–9433 24 68.0
WT (F) CCTCCTCCTGCCATACCCG 9023–9041 19 434 66.6
Mut (F) CCTCCTCCTGCCATACCCA 9023–9041 19 434 64.5
for VKORC1 381, 861, 5808, and 9041, respectively. Thermal
cycling conditions are similar for both PCR1 and PCR2 except
for the annealing temperature for PCR1 which was at 63.5∘C,
while for PCR2 it was at 64.8∘C. Both PCR reactions were
run for 25 cycles. Optimised gel electrophoresis images for
optimised multiplex PCR1 are shown in Figure 1, while the
representative images for PCR2 are shown in Figure 2. The
genotypes determined by the optimised PCR2 were in 100%
concordance with the DNA sequencing data. The repro-
ducibility of the method was confirmed by the successful
amplification of all 92 additional DNA samples. Genotype
and haplotype frequency for all of the subjects are shown in
Table 3. The haplotypes in 31 subjects could not be accurately
determined whether as H1H7 or H1H9 because they were
heterozygous for both VKORC1 381 and 9041, leading to
inconclusive results from the haplotyping tree. The finding
was comparable with what has been discovered by Lee et al.
[10], where in this investigation the frequency of H1H1 was
53.76% (compared with 42%), H1H7 or H1H9 was 34.41%
(compared with 42%), H7H7 was 8.6% (compared with 8%),
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Table 3: Genotype frequency of individual VKORC1 SNPs and haplotype frequency in 93 subjects.
Number of patients (%)
Homozygous wild type Heterozygous Homozygous mutant
VKORC1 381 (C>T) 51 (54.84) 33 (35.48) 9 (9.68)
VKORC1 861 (C>A) 91 (97.85) 0 (0) 2 (2.15)
VKORC1 5808 (G>A) 92 (98.92) 1 (1.08) 0 (0)
VKORC1 9041 (T>G) 51 (54.84) 33 (35.48) 9 (9.68)
Number of patients (%)
H1H1 50 (53.76)
H1H2 1 (1.08)
H1H7a 1 (1.08)
H1H7 or H1H9a 31 (33.33)
H1H9 1 (1.08)
H7H7 8 (8.6)
H8H9 1 (1.08)
a“H1H7 or H1H9” was considered as “H1H7,” in concordance with previous investigation findings, where H1H9 was uncommon in Asia.
011 012 013 −ve100 bp
Figure 1: Optimised multiplex amplification for PCR1. 100 bp:
100 bp ladder; −ve: negative control.
and the remaining haplotypes were 3.23% (compared with
0%).
4. Discussion
It is rather common for a multiplex PCR reaction to
yield bands with unequal brightness. Therefore, individual
samples, especially those which produced faint bands for
VKORC1 381 in PCR1, can be reamplified using higher
amounts of DNA template. For PCR2, the intensity of
VKORC1 381 band was increased by reamplifying faint bands
following the addition of 2.5% dimethyl sulfoxide (DMSO)
into the PCR mixture. However, even though the addition of
DMSO improved the brightness of theVKORC1 381 band, the
occurrence of nonspecific bands at the region of the 700 bp
also increased without compensating the readings.
Among the 93 tested patients, 31 patients had an unclear
haplotype; that is, it could not be determined whether the
patients were H1H7 orH1H9. For the purpose of comparison,
it is safe to assume that the patients with unclear haplotype
have haplotype H1H7 due to the absence of H1H9 haplotype
in previous investigations [10, 11]. Nevertheless, a measure
to improve the distinction between H1H7 and H1H9 is still
possible by adding another VKORC1 variant primer pair
such as VKORC1 6484 (also known as VKORC1 1173 C>T)
which has been found to be present in complete linkage
disequilibrium together with VKORC1 9041 [20] into PCR2
amplifications which can be further investigated in future
studies. Other than VKORC1 381 (and its linked alleles),
VKORC1 5808 also played a major role in determining the
VKORC1 haplotype. In a previously reported simple method
for determining VKORC1 haplotypes [11], any heterozygous
H1 haplotype was assumed to be H1H7 (combination of
low and high dosage requirement) because other possible
haplotypes like H1H8 and H1H9 haplotype are exceptionally
rare in the Asian population. However, the oversimplified
genotyping method was shown to cause overestimation of
daily warfarin dose [11], which proved that each of H7,
H8, and H9 may affect the warfarin dose differently, even
though three of the haplotypes were classified under the same
“high warfarin dose” group [9]. The finding also supports
that the occurrence of rare haplotypes like H8 and H9 was
still possible in the Asian population. Therefore, additional
identification of other VKORC1 SNPs in addition to VKORC1
381 is an essential step that should not be overlooked.
Malaysia is a country which consists of three major
ethnic groups, namely, the Malays, Chinese, and the Indians
with distinct genotypic frequency and polymorphisms. In
this study, only VKORC1 polymorphisms among the Malay
populations were investigated since the Malay is the major
ethnic group found in the study region (Kelantan).TheMalay
ethnic group, to some extent, can represent the genotypic
distribution of the Chinese population due to reported
similar polymorphic frequency in certain genes [21]. The
Indian population, however, is a very distinct ethnic group
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Figure 2: Representative gel electrophoresis result for PCR2. Genomic DNA from six unrelated subjects (001–005) was used as DNA
templates. 100 bp = 100 bp ladder; −ve = negative control; +ve = positive control.
where certain warfarin-related mutant strain SNPs such as
the CYP2C9∗2 and ∗3 and VKORC1 −1639G were reported
to be higher in frequency among the Indians when compared
with the Malays and the Chinese [22, 23]. Therefore, future
studies investigating the VKORC1 haplotypes among the
Indians are important to thoroughly represent the VKORC1
haplotype in the Malaysian population.
All VKORC1 genotypic frequencies were found to be in
Hardy-Weinberg equilibrium except for the VKORC1 861
CA and AA which may be underestimated (observed =
0, expected = 0.29) and overestimated (observed = 0.0215,
expected = 0), respectively. This could be contributed by
either the small sample size or the low frequency of the allele
in this population (or both). Nevertheless, should the 861 CA
occur, the only possible haplotype for the subject is H7H8. A
previous study [10] in an Asian population utilising similar
sample size also found low frequencies of H7H8. Therefore,
future studies intending to investigate the frequency of the
H7H8 haplotypewill requiremuch larger sample size to avoid
deviation in Hardy-Weinberg equilibrium.
To our knowledge, this is the first PCR method that can
simultaneously amplify multiple VKORC1 alleles. Although
there are many PCR methods available for the genotyp-
ing of single VKORC1 SNPs, the prediction accuracy of
multiple VKORC1 SNPs will certainly be superior to those
of single SNP. The addition of only few primer pairs in
genotyping proved to yield very detailed haplotype data
when compared with genotypic data generated by single-
SNP PCR. This multiplex PCR method is an advantage
especially for laboratories which are not equipped with
automated sequencers. Otherwise, direct sequencing of the
whole (small-sized) VKORC1 gene would be the method
of choice for haplotyping patients under warfarin treatment
in order to detect rare but potentially unknown variants in
VKORC1. Moreover, the developed method was economical
and can be conducted using only basic molecular tools that
are available in most laboratories. The haplotyping method
is easy to use and allows the VKORC1 gene to be haplotyped
without the necessity of whole-gene sequencing.Thismethod
was successfully used to investigate the frequency ofVKORC1
haplotypes in a small group of Malaysian patients.
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